Artemis Investment Management LLP increased its stake in Amgen Inc. (NASDAQ:AMGN) by 4.1% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 191,204 shares of the medical research company’s stock after buying an additional 7,553 shares during the period. Artemis Investment Management LLP’s holdings in Amgen were worth $29,096,000 as of its most recent SEC filing.
A number of other large investors also recently added to or reduced their stakes in the company. Wilbanks Smith & Thomas Asset Management LLC increased its position in shares of Amgen by 5.4% in the first quarter. Wilbanks Smith & Thomas Asset Management LLC now owns 5,896 shares of the medical research company’s stock worth $884,000 after buying an additional 301 shares during the last quarter. DAVENPORT & Co LLC increased its position in shares of Amgen by 0.4% in the first quarter. DAVENPORT & Co LLC now owns 238,686 shares of the medical research company’s stock worth $35,786,000 after buying an additional 934 shares during the last quarter. Duncker Streett & Co. Inc. increased its position in shares of Amgen by 7.7% in the first quarter. Duncker Streett & Co. Inc. now owns 2,804 shares of the medical research company’s stock worth $421,000 after buying an additional 200 shares during the last quarter. Douglas Lane & Associates LLC acquired a new position in shares of Amgen during the first quarter worth about $51,117,000. Finally, First Manhattan Co. increased its position in shares of Amgen by 0.9% in the first quarter. First Manhattan Co. now owns 265,999 shares of the medical research company’s stock worth $39,881,000 after buying an additional 2,500 shares during the last quarter. 79.15% of the stock is currently owned by institutional investors and hedge funds.
Amgen Inc. (NASDAQ:AMGN) traded down 0.20% during midday trading on Thursday, hitting $166.90. The stock had a trading volume of 1,904,070 shares. The company has a market cap of $124.90 billion, a PE ratio of 17.08 and a beta of 0.94. The firm has a 50-day moving average of $170.96 and a 200-day moving average of $161.68. Amgen Inc. has a 12-month low of $139.02 and a 12-month high of $176.85.
Amgen (NASDAQ:AMGN) last released its quarterly earnings data on Wednesday, July 27th. The medical research company reported $2.84 EPS for the quarter, beating analysts’ consensus estimates of $2.74 by $0.10. Amgen had a return on equity of 29.30% and a net margin of 33.07%. The firm had revenue of $5.69 billion for the quarter, compared to analysts’ expectations of $5.58 billion. During the same period in the prior year, the firm posted $2.57 earnings per share. The firm’s quarterly revenue was up 5.9% on a year-over-year basis. Equities research analysts forecast that Amgen Inc. will post $11.35 EPS for the current year.
The firm also recently disclosed a quarterly dividend, which was paid on Thursday, September 8th. Investors of record on Wednesday, August 17th were issued a $1.00 dividend. This represents a $4.00 dividend on an annualized basis and a yield of 2.40%. The ex-dividend date of this dividend was Monday, August 15th. Amgen’s dividend payout ratio is presently 40.90%.
AMGN has been the topic of a number of research analyst reports. Vetr downgraded Amgen from a “hold” rating to a “sell” rating and set a $166.35 price target on the stock. in a report on Monday, August 1st. Goldman Sachs Group Inc. reaffirmed a “buy” rating and set a $204.00 price target on shares of Amgen in a report on Thursday, September 8th. Cowen and Company reaffirmed a “buy” rating on shares of Amgen in a report on Monday, September 19th. Jefferies Group reaffirmed a “buy” rating and set a $187.00 price target on shares of Amgen in a report on Wednesday, July 13th. Finally, Piper Jaffray Cos. reaffirmed a “buy” rating and set a $193.00 price target on shares of Amgen in a report on Thursday, July 28th. One investment analyst has rated the stock with a sell rating, nine have assigned a hold rating and twelve have given a buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus price target of $184.94.
In related news, VP Annette Louise Such sold 3,000 shares of the company’s stock in a transaction that occurred on Tuesday, August 2nd. The stock was sold at an average price of $174.59, for a total value of $523,770.00. The transaction was disclosed in a legal filing with the SEC, which is available through this link. 0.20% of the stock is owned by corporate insiders.
Amgen Company Profile
Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. The Company’s business segment is human therapeutics. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as Vectibix (panitumumab), Nplate (romiplostim) and Corlanor (ivabradine).